Global Cell Therapy Market is Expected to Reach $8.21 bn by 2026

06 September, 2019

The Global Cell Therapy Market was valued at US$3.06 billion in the year 2018 and is expected to reach US$8.21 billion by 2026, at a CAGR of 13.1%.

Cell therapy offers the promise of treating and altering the course of diseases which cannot be addressed adequately by the existing therapeutic modalities. Initially, blood transfusion was considered to be the first type of routine cell therapy practice. Later, Bone marrow transplantation came into existence and became a well-established method for treating disorders including anemia, leukemia, lymphoma and rare immunodeficiency diseases. Medical practitioners also performed cell therapy under different names such as xenotransplant therapy, glandular therapy, and fresh cell therapy. It has also been acclaimed that cell therapy has been used successfully to repair spinal cord injuries, strengthen the weakened immune system, treat autoimmune diseases including AIDS and also help patients ailing from neurological disorders like Alzheimer’s disease, Parkinson’s disease, epilepsy and many more.

There is a developing interest in cell therapy because of the expanding concerns identified with organ transplants. The implementation of conventional strategies brings about a few complexities, for example, gastrointestinal problems, high blood pressure, diabetes, high cholesterol, graft rejection, immunosuppression and risk of infection. The accessibility of human cells and the absence of reasonable tissue composition are additionally driving the interest in cell therapy. The developing rates of chronic diseases that drive the requirement for safeguarding umbilical cord blood stem cells are additionally driving the cell therapy market.

Regulatory bodies are involved in providing support to innovators for introducing innovative and effective solutions for patients. However, well-established companies are working in collaboration with regulatory bodies that provide ample opportunities. However, ethical and religious concerns related to stem cell research might restrain the revenue generation during the forecast period.

More than 150 companies are present in the field of cell therapy and more and more technologies are being discovered. The long-term strategy for market sustenance and attaining leadership in the sector will occur through partnerships and collaborations with blood centers and plasma collection centers to obtain cells to be used in therapeutic development. For instance, in February 2017, Vericel Corporation conducted its first implant of MACI (autologous cultured chondrocytes on porcine collagen membrane) in the U.S. for treating symptomatic multiple or single full-thickness cartilage defects of the knee. Post this, the organization had started channelizing its methodologies to build the number of specialists utilizing its products in transplantation methodology. Companies such as Novartis AG, Anterogen Co, Pharmicell, etc., are also keen on launching their products depending upon the competition, pricing, etc.

Optima Insights had classified the cell therapy market based on the type, technology, cell source, application, end-user, and regions.

The Autologous segment occupied the largest market share in terms of treatment types in 2018. Autologous cell therapy refers to the injection of human tissue or cells to a similar individual to treat pathological conditions. For a similar reason, the undifferentiated cells are removed from the patient, harvested, cultured, and transplanted again to the same person. Focal points of Autologous cell therapy include minimization of risks from systemic immunological reactions, bio-incompatibility, and disease transmission related to grafts or cells not cultivated from the individual.

Ex vivo gene therapy captured the largest market share in the technological domain during 2018 due to gene modifications using viral vector technology for cell therapy and also is used in several types of cells, the most common being Hematopoietic stem cells (HSCs), Mesenchymal stem cells (MSCs) and T cells. Gene modifications of HSCs showed promising results for diseases like ADA SCID (adenosine deaminase severe combined immunodeficiency disease) while gene-modified MSCs are entering the first clinical trials for indications such as advanced adenocarcinoma. In the case of T cells, which are currently the dominating cell type in this field, the approach is to genetically modify the T cells and used them to target specific cancers.

Induced Pluripotent Stem Cells (iPSCs) are the largest type of cells that were used for treatment until the year 2018 due to it offering a promising innovative approach for pain treatment. An increasingly focused methodology and reassessment of therapeutic objectives may also contribute to the overall efficacy, as well as to the clinical acceptance of regenerative treatments.

In 2018, the musculoskeletal segment was the largest disease type that received cell therapy, worldwide. Cell therapy is designed to treat different types of musculoskeletal-related pain. Also, mesenchymal cell-based therapies are already being tested in various clinical trials that treat musculoskeletal system-related pain as the primary or secondary endpoint.

Due to huge investments in research and development for discovery of viable cellular therapies, research institutes contributed more towards the growth of the global market share and due to the high acceptance of advanced therapy (including cell expansion systems and single-use equipment) in cell-based experiments and cancer research as well as the growing number of R&D facilities globally.

Europe is a high-income nation and typically spends 2% to 3% of their annual health budget on the treatment of chronic diseases as per the bulletin published by the World Health Organization. Components responsible for market growth in this region are existing healthcare infrastructure and the rise in the adoption of cell therapy for orthopedic, cancer, and wound healing.  

Companies such as Advanced Tissue, Cognate Bioservices Inc., Cellectis, Fibrocell Science, Inc., Sanofi Genzyme. Beijing Tricison biotherapeutics Inc., Guangzou Trinomab Biotech Co., Ltd, JCR Pharmaceuticals, BioNTech IMFS, EUFETS GmbH, etc. These organizations started channelizing their policies to increase the number of specialists utilizing their products in transplantation techniques.

The Cell Therapy Market Outlook 2019-2026, from Optima Insights, will offer a thorough insight on the market growth till the forecast year 2026 based on the market segmentation (type, technology, cell source, application, end-use, and region). The report also comprises comprehensive profiling of companies involved in Cell Therapy, product information and pipeline information.

Request for Sample Pages @ https://www.optimainsights.org/sample-request/104-cell-based-therapies-market

The Report Provides Key Insights on


  • History of the Cell Therapy Market, 2015 to 2017

  • Forecast of the Cell Therapy Market Growth till the year 2026

  • The key market drivers, restraints, challenges, future opportunities and the market dynamics driving the Cell Therapy Market

  • Analysis of potential growth segments which will drive the market

  • Landscape analysis of the major companies, and new market entrants and companies which possess disruptive technologies which can change the trend of the entire market

  • Key market approaches adopted by the organizations and in-depth intelligence of potential strategies which could alter the market dynamics

Cell Therapy Market Based on Type (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)


  • Autologous Cell Therapy

  • Allogenic Cell Therapy

Cell Therapy Market Based on Application (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)


  • Musculoskeletal

  • Cardiovascular

  • Gastrointestinal

  • Neurological

  • Oncology

  • Dermatology

  • Wounds and injuries

  • Ocular

Cell Therapy Market Based on Cell Source (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)


  • Induced pluripotent stem cells (iPSCs)

  • Bone marrow-derived cells

  • Umbilical cord blood-derived cells

Cell Therapy Market Based on End-User (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)


  • Hospitals and Clinics

  • Research Institutes

Cell Therapy Market Based on Geographic Region (Market Size and Forecast, and Y-o-Y Growth, (US$ Mn)


  • North America

  • Europe

  • APAC

  • LAMEA

Cell Therapy Market Competitive Analysis (Company Overview, SWOT Matrix, Financial, Product Overview, and Market Strategies)


  • Novartis AG

  • GlaxoSmithKline Plc

  • Stemedica Cell Technologies, Inc.

  • Vericel Corporation


  • BioNTech IMFS GmbH



  • NuVasive, Inc.



  • Sanofi S.A.


Download Complete TOC of the Report @ https://www.optimainsights.org/request-toc/104-cell-based-therapies-market

About Us

Optima Insights is an innovative research and insights-driven enterprise committed to offering actionable intelligence to the global life science and healthcare market. We believe that meaningful insights and improved strategic content hold the key to improved ROI for our clients. We strike an innovative engagement model with our clients to Co-Create Intelligence that would address very specific issues facing them within their functional areas. We continuously support clients through the entire journey map to enable them to make better business decisions towards attaining market leadership.

Contact

Optima Insights

Mr Chucks G

+91 966 6620 365 (Asia) | +1 424 2554 365 (US)

Email: info@optimainsights.org

https://www.optimainsights.org